Stock Analysis
- South Korea
- /
- Personal Products
- /
- KOSDAQ:A241710
Cosmecca Korea Co., Ltd.'s (KOSDAQ:241710) Intrinsic Value Is Potentially 73% Above Its Share Price
Key Insights
- Cosmecca Korea's estimated fair value is ₩132,065 based on 2 Stage Free Cash Flow to Equity
- Current share price of ₩76,300 suggests Cosmecca Korea is potentially 42% undervalued
- The ₩89,000 analyst price target for A241710 is 33% less than our estimate of fair value
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Cosmecca Korea Co., Ltd. (KOSDAQ:241710) as an investment opportunity by taking the expected future cash flows and discounting them to their present value. This will be done using the Discounted Cash Flow (DCF) model. Believe it or not, it's not too difficult to follow, as you'll see from our example!
Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model.
View our latest analysis for Cosmecca Korea
The Model
We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
Generally we assume that a dollar today is more valuable than a dollar in the future, and so the sum of these future cash flows is then discounted to today's value:
10-year free cash flow (FCF) estimate
2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | |
Levered FCF (₩, Millions) | ₩48.0b | ₩57.4b | ₩64.4b | ₩70.4b | ₩75.5b | ₩80.0b | ₩83.9b | ₩87.4b | ₩90.6b | ₩93.6b |
Growth Rate Estimate Source | Analyst x4 | Analyst x3 | Est @ 12.22% | Est @ 9.33% | Est @ 7.30% | Est @ 5.87% | Est @ 4.88% | Est @ 4.18% | Est @ 3.70% | Est @ 3.36% |
Present Value (₩, Millions) Discounted @ 7.6% | ₩44.6k | ₩49.6k | ₩51.7k | ₩52.5k | ₩52.4k | ₩51.5k | ₩50.2k | ₩48.6k | ₩46.9k | ₩45.0k |
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = ₩493b
The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 2.6%. We discount the terminal cash flows to today's value at a cost of equity of 7.6%.
Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = ₩94b× (1 + 2.6%) ÷ (7.6%– 2.6%) = ₩1.9t
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= ₩1.9t÷ ( 1 + 7.6%)10= ₩917b
The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is ₩1.4t. The last step is to then divide the equity value by the number of shares outstanding. Compared to the current share price of ₩76k, the company appears quite undervalued at a 42% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind.
The Assumptions
The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Cosmecca Korea as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 7.6%, which is based on a levered beta of 1.067. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for Cosmecca Korea
- Earnings growth over the past year exceeded the industry.
- Debt is not viewed as a risk.
- No major weaknesses identified for A241710.
- Annual revenue is forecast to grow faster than the South Korean market.
- Trading below our estimate of fair value by more than 20%.
- Annual earnings are forecast to grow slower than the South Korean market.
Next Steps:
Valuation is only one side of the coin in terms of building your investment thesis, and it ideally won't be the sole piece of analysis you scrutinize for a company. DCF models are not the be-all and end-all of investment valuation. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation. What is the reason for the share price sitting below the intrinsic value? For Cosmecca Korea, we've compiled three fundamental aspects you should further examine:
- Financial Health: Does A241710 have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
- Future Earnings: How does A241710's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!
PS. Simply Wall St updates its DCF calculation for every South Korean stock every day, so if you want to find the intrinsic value of any other stock just search here.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About KOSDAQ:A241710
Cosmecca Korea
Engages in the research and development, manufacture, and sale of skincare products in South Korea and internationally.